According to the II level neuropsychological evaluation, 4.8 % of MSA patients met criteria for dementia and 53,2 % for MCI. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
According to the II level neuropsychological evaluation, 4.8 % of MSA patients met criteria for dementia and 53,2 % for MCI. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This case report explores the therapeutic potential of lymphovenous bypass (LVB) surgery performed at the neck in neurodegenerative diseases, specifically Alzheimer's disease (AD) dementia. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
90%) rated the app favorably, stating it was enjoyable and easy to complete unsupervised. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Most factors of the MoCA-B were significantly different between the two groups, and the PSCN group completed the MoCA-B faster (p 0.05). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We observed measurement differences in the HCAP across H/L and NHW older adults for the memory, language, executive functioning, and orientation, but not visuospatial, domains. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patients with PDD showed a more severe phenotype than those with DLB, with higher scores in motor severity, hallucinations, delusions, somnolence, and urinary dysfunction (all p≤0.01). 5 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four themes described current primary care practitioner practices in dementia diagnosis and management (1) Family concern triggers dementia investigation (2) GPs delay conversations about dementia (3) Completing routine cognitive assessments in the 75+ health assessment, and (4) Variability in post-diagnostic care. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants had age mean = 81.7, SD = 4.5, range=75-93; educational attainment mean = 14.6, SD = 4.0, range=7-22, 17.2% < 12; 86.2% were women. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fourteen studies met eligibility criteria, covering populations from healthy controls to individuals with subjective cognitive decline, MCI, AD, and other dementias. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study provides validated conversion tables between the Q mci screen and two widely-used cognitive instruments, to support the use of the Q mci screen in research (facilitating cross-instrument comparability and harmonization across studies), and clinical settings (determining eligibility for disease-modifying therapies). 2 key findings →
Participants: 101 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Juxtacortical free water fraction, determined at diffusion MRI, was higher in participants with Alzheimer disease compared with cognitively normal controls and associated with amyloid-β, tau, and neurodegeneration biomarkers, revealing two distinct spatiotemporal progression patterns with different impacts on neuroanatomic signatures and cognitive performance. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We aim to compare the biological staging of Alzheimer Disease using two different tau PET tracers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
[18F]GTP1 exhibited retention patterns that correlated with [18F]PI-2620 and [18F]MK-6240 for all Braak regions (except Braak II). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14]. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Brain functional connectivity alterations, that is, pathological changes in the signal exchange between areas of the brain, are occurring in several neurological diseases, including neurodegenerative and neuropsychiatric ones. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's Disease and Related Dementias (AD/ADRD) are progressive neurodegenerative conditions that impair memory, thought processes, and functioning. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We identified two main themes (each with subthemes) that influence Latino dementia caregiver experiences with healthcare: (1) caregiving and understanding of dementia shaped by individual, family, and social factors (subthemes: Caregiver's own understanding of dementia; Lack of support and understanding from family; Latino cultural perspectives on dementia); and (2) navigating formal services amid gaps in cultural alignment and support (subthemes: Trial and error: education and resource gaps; Cultural tension with healthcare). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Spousal caregivers of persons living with dementia (PLwD) often experience high overload and loneliness due to the intensive and ongoing nature of caregiving for their partner. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Informal caregivers of patients with neurodegenerative diseases are confronted with significant psychological distress. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Adults of 78.8 years on average, with low to middle socio-economic status, low education levels, and multiple comorbidities, have adverse well-being and support conditions, except for the spiritual component. 5 key findings →
Participants: 73 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The CES effectively distinguished between different levels of caregiver strain. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Assistive technologies hold significant potential to enhance the quality of life for persons with dementia and their caregivers by addressing key concerns related to safety, independence, and social inclusion. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 11 dyads participated in the study. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events